Generali Asset Management SPA SGR Increases Stock Holdings in Medtronic PLC $MDT

Generali Asset Management SPA SGR raised its position in Medtronic PLC (NYSE:MDT) by 71.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 70,065 shares of the medical technology company’s stock after acquiring an additional 29,181 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Medtronic were worth $6,673,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of MDT. Brighton Jones LLC increased its stake in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares during the period. Aprio Wealth Management LLC acquired a new position in shares of Medtronic in the first quarter worth $297,000. Hancock Whitney Corp increased its position in shares of Medtronic by 1.7% during the first quarter. Hancock Whitney Corp now owns 29,097 shares of the medical technology company’s stock worth $2,615,000 after acquiring an additional 478 shares during the period. Integrated Wealth Concepts LLC raised its stake in shares of Medtronic by 23.3% in the first quarter. Integrated Wealth Concepts LLC now owns 52,162 shares of the medical technology company’s stock valued at $4,687,000 after acquiring an additional 9,868 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Medtronic by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 241,630 shares of the medical technology company’s stock valued at $21,695,000 after acquiring an additional 13,973 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of MDT opened at $96.03 on Friday. The company has a market capitalization of $123.11 billion, a price-to-earnings ratio of 25.88, a price-to-earnings-growth ratio of 2.53 and a beta of 0.71. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock has a 50 day moving average price of $97.65 and a 200 day moving average price of $94.01.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the previous year, the firm earned $1.26 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio is currently 76.55%.

Wall Street Analyst Weigh In

Several research firms recently commented on MDT. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday. Barclays raised their target price on shares of Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, November 20th. Morgan Stanley boosted their price target on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Finally, Robert W. Baird set a $103.00 price objective on shares of Medtronic in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).